Table 1 Baseline and follow-up characteristics of HIV-infected women in the MTCT-Plus program (N = 290).

Period at HAART initiation

   Pregnant/non pregnant, n (%)

Exposed women to PMTCT

   Exposed/no exposed, n (%)

Age, years, median [IQR]

   >29 years

Body mass index, Kg/m² [IQR]

   >18.5 *

WHO clinical stage, n (%)

   1

   2

   3

   4

CD4 counts, cells/mm³ [IQR]

   >250

Co-trimoxazole, n (%)

Haemoglobin level, g/l, median [IQR]

   ≤9.8

Neutrophil count, mm³, median [IQR]

   <1500

HAART regimen, n (%)

   ZDV/3TC/NVP

   d4T/3TC/NVP

Alanine aminotransferase, UI, median [IQR]

   <31 IU/L*

Aspartate aminotransférase, UI, median [IQR]

   <32 IU/L*

Follow-up

Cumulative, person-months

Per patient, months, median [IQR]

Status on study termination

   Dead, n (%)

   Lost to follow-up, n (%)

   Alive, n (%)